164 related articles for article (PubMed ID: 36982938)
1. Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC).
Cordani N; Lisini D; Coccè V; Paglia G; Meanti R; Cerrito MG; Tettamanti P; Bonaffini L; Paino F; Alessandri G; Marcianti A; Giannì A; Villa C; Mauri M; Mologni L; Torsello A; Pessina A; Cazzaniga ME
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982938
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
[TBL] [Abstract][Full Text] [Related]
4. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-
Wang X; Gao J; Ouyang X; Wang J; Sun X; Lv Y
Int J Nanomedicine; 2018; 13():5231-5248. PubMed ID: 30237710
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.
Eiro N; Fraile M; Escudero-Cernuda S; Sendon-Lago J; Gonzalez LO; Fernandez-Sánchez ML; Vizoso FJ
Stem Cell Res Ther; 2024 Apr; 15(1):121. PubMed ID: 38664697
[TBL] [Abstract][Full Text] [Related]
7. Nanomicellar Formulations Loaded with Histamine and Paclitaxel as a New Strategy to Improve Chemotherapy for Breast Cancer.
Nicoud MB; Ospital IA; Táquez Delgado MA; Riedel J; Fuentes P; Bernabeu E; Rubinstein MR; Lauretta P; Martínez Vivot R; Aguilar MLÁ; Salgueiro MJ; Speisky D; Moretton MA; Chiappetta DA; Medina VA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834958
[TBL] [Abstract][Full Text] [Related]
8. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
Ye J; Xia X; Dong W; Hao H; Meng L; Yang Y; Wang R; Lyu Y; Liu Y
Int J Nanomedicine; 2016; 11():4125-40. PubMed ID: 27601899
[TBL] [Abstract][Full Text] [Related]
9. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.
Liu M; Gong C; Xu R; Chen Y; Wang X
Cell Mol Biol Lett; 2019; 24():47. PubMed ID: 31308851
[TBL] [Abstract][Full Text] [Related]
11. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
12. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody.
Liu J; Wang P; Huang B; Cheng Q; Duan Y; Chen L; Ma T; Zhu C; Li D; Fan W; Yu M
Int J Pharm; 2022 Aug; 624():121969. PubMed ID: 35803533
[TBL] [Abstract][Full Text] [Related]
13. A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy.
Liu Y; Hong G; Mao L; Su Z; Liu T; Liu H
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175072
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
Zhao PW; Cui JX; Wang XM
Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
[TBL] [Abstract][Full Text] [Related]
15. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
[TBL] [Abstract][Full Text] [Related]
16. Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines.
Wilhelm CA; Clor ZJ; Kelts JL
Anticancer Res; 2018 Sep; 38(9):5043-5048. PubMed ID: 30194148
[TBL] [Abstract][Full Text] [Related]
17. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
Sha LY; Zhang Y; Wang W; Sui X; Liu SK; Wang T; Zhang H
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2201-8. PubMed ID: 27338043
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
Chen DR; Lu DY; Lin HY; Yeh WL
Biomed Res Int; 2014; 2014():532161. PubMed ID: 25140317
[TBL] [Abstract][Full Text] [Related]
19. CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
Yi M; Peng C; Xia B; Gan L
Clin Breast Cancer; 2022 Feb; 22(2):e191-e198. PubMed ID: 34284965
[TBL] [Abstract][Full Text] [Related]
20. EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer.
Burande AS; Viswanadh MK; Jha A; Mehata AK; Shaik A; Agrawal N; Poddar S; Mahto SK; Muthu MS
AAPS PharmSciTech; 2020 May; 21(5):151. PubMed ID: 32440910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]